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For all drugs, the therapeutic ratio, i.e, the difference between therapeutic effect and adverse effect, 
should be as large as possible. When focusing on drugs used in the treatment of asthma, particularly 
P2-agonists and corticosteroids, the therapeutic ratio of these drugs can be considered to be the degree of 
separation of their effects on lung function from their systemic effects. This is increased by administration 
via inhalation, resulting in targeting of the drug directly to the site of action. However, all drugs 
deposited in the airways are eliminated via the systemic circulation, and have, therefore, the potential to 
cause some systemic side effects. 
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Short-acting P,-agonists 
An early study by Thiringer & Svedmyr (l), showed 
that lung function improved more with inhaled terbu- 
taline than with systemically administered drug. 
Furthermore, the systemic side-effects of the beta-2- 
agonist, given by the inhaled route was substantially 
reduced, showing that the therapeutic ratio is 
improved when anti-asthma drugs are given by 
inhalation. 
peutic ratio of an inhaled J&agonist by optimising 
airway distribution, thereby giving it exactly to the 
site where it exerts its effect. This could perhaps be 
achieved by using inhalers delivering monodispersed 
aerosols of a particular particle size (5) 
Long-acting P,-agonists 
In some studies, increased deposition of inhaled 
beta-2-agonists has been found by using different 
inhalation devices. For example, inhaled terbutaline 
is deposited to a larger extent in the lung (2) when 
using the TurbuhalerTM (18-2 1 “A) compared with the 
pMD1 (9%). This increased deposition of terbutaline 
is associated with a more pronounced improvement 
in lung function (2,3) suggesting that the degree of 
deposition is important in determining the degree of 
bronchodilation. However, it is likely that increasing 
overall lung deposition of a beta-2-agonist will result 
in larger systemic bioavailability of the drug, and 
will therefore most likely also increase systemic side 
effects, such as tremor (4) and changes in serum 
potassium and heart rate, in parallel with local ben- 
eficial effects. Thus, the therapeutic ratio may not 
necessarily be improved by simply increasing lung 
deposition. It may be possible to increase the thera- 
When an inhaled bronchodilator drug reaches the 
airway wall, it will have to diffuse through the airway 
epithelium to reach the submucosa, and then be 
further transported through the submucosa to the 
airway smooth muscle, before exerting its effects. 
The microenvironmenta distribution of drugs in 
the airways has been mainly discussed in the context 
of long-acting beta-2-agonists (6). Salmeterol and 
formoterol are two long-acting, &agonists that 
have been studied extensively, both clinically and in 
in vitro systems. A clinical difference between the 
two drugs is seen in their onset of action, whereas 
the duration of effect can be shown to be very similar 
(7). Thus, both in isolated airway smooth muscle 
(6,8), and in patients (9,10), the onset of action of 
formoterol is faster than that of salmeterol. 
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It has been hypothesised that the different onset of 
action of these two drugs may depend on their 
different ways of entering the active site of the beta- 
2-receptor (6). Both salmeterol and formoterol are 
lipophilic, and a large proportion of drug in the 
microenvironment will be taken up into the lipid 
bilayer of the cell membrane, and a smaller portion 
will remain in the hydrophilic extracellular space. 
Salmeterol is taken up to a larger extent into the 
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membrane compared with formoterol(6), because of 
its higher lipophilicity. 
The long-acting beta-Zagonists may diffuse into 
the active site of the beta-Zreceptor by two different 
routes, from the extracellular space and from the 
lipid bilayer. Formoterol, being less lipophilic than 
salmeterol, may to a larger extent enter the beta-2- 
receptor from the extracellular space, a process which 
will be more rapid than that of salmeterol, which 
enters exclusively from the lipid bilayer, explaining 
the faster onset of action of formoterol (810). 
The duration of effect of both of these &agonists 
may in part be explained by the membrane lipid 
bilayer acting as a depot, allowing drug to be 
presented to the beta-2-receptor over a prolonged 
period of time. However, for salmeterol it has also 
been suggested that binding to an exo-site, within the 
beta-2-receptor, is important for the long duration of 
action (11). 
Inhaled Corticosteroids 
Giving corticosteroids by the inhaled route improves 
substantially the therapeutic ratio compared with the 
oral route. For example, inhaled budesonide is 
suggested to be approximately 30-50 times more 
potent in improving asthma control than oral 
prednisolone (12), whereas oral prednisolone is 
approximately 7 times more potent in inducing 
steroid-related systemic side-effects (measured as 
decrease in serum cortisol levels). 
Inhaled corticosteroids may have their most pro- 
nounced effect in airway epithelial cells, in tissue 
resident inflammatory cells, and in the endothelium 
of the airway wall microvasculature. It is therefore 
likely that the concentration of a corticosteroid 
within the airway wall is important for its clinical 
effect, but very little is known about the micro- 
environmental distribution of inhaled steroids in the 
lung. In man, inhalation of budesonide and flutica- 
sone propionate results in a high local concentrations 
of drug in both central and peripheral lung tissue 
(13-l 5) within the range showing anti-inflammatory 
effects in vitro, whereas the concentration in the 
plasma (13,14) is lower at corresponding time 
points. This was particularly evident for fluticasone 
propionate (14), where the high local concentrations 
were maintained for more than 12h, probably due to 
slower elimination from the airways (16). This would 
indicate that there is considerable binding of flutica- 
sone propionate in the lung, which may, in part, 
result in a prolonged residency time of the drug at the 
important sites of action, and may result in a longer 
duration of clinical effect. 
When a corticosteroid is given by inhaled route, 
approximately 15-30% of the emitted dose reaches 
the lung, and the rest is deposited in the mouth and 
pharynx. Most of the drug deposited outside the lung 
will be swallowed and absorbed from the GI tract, 
but up to 80-99% may be eliminated by first-pass 
metabolism in the liver. All of the drug deposited in 
the lung, and the oral portion not eliminated by first 
pass metabolism, will reach the systemic circulation. 
One study has investigated whether the fraction of 
corticosteroid reaching the systemic circulation has 
any anti-asthma effects (17). Briefly, budesonide was 
given orally at a dose causing a systemic concen- 
tration of the drug, similar to that found after inhaled 
drug. No beneficial anti-asthma effect was, however, 
observed suggesting strongly that the most important 
site of action of inhaled corticosteroids is the airways, 
and that any systemic anti-inflammatory effects may 
be unimportant for anti-asthma efficacy. 
Conclusions 
Improving knowledge of the microenvironmental 
distribution of topically administered anti-asthma 
drugs may prove to be important. For example, 
increased therapeutic ratio may be achieved by 
decreasing the elimination of inhaled drugs from the 
airways, thus increasing and maintaining their con- 
centration at the site of airflow obstruction and 
inflammation in asthma. In the future, the same goal 
may be reached by targeting the drug to its site of 
action, by using monodispersed aerosols. 
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